66537-55-1

66537-55-1 structure
66537-55-1 structure

Name (2S)-N-[(2S)-1-[(4S)-4-Carbamoyl-1,3-thiazolidin-3-yl]-3-(1H-imid azol-5-yl)-1-oxo-2-propanyl]-6-oxo-2-piperidinecarboxamide
Synonyms <*>Aad-His-Tzl-NH2
{2S-[2R*(R*(R*))]}-N-{2-[4-(aminocarbonyl)-3-thiazolidinyl]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl}-6-oxopiperidine-2-carboxamide
{2-Methyl-4-[bis-(2-jod-ethyl)-amino]-benzyliden}-malononitril
{4-[bis(2-iodoethyl)amino]-2-methylbenzylidene}propanedinitrile
Description MK771 is a thyrotrophin-releasing hormone analog. MK771 induces blinking and forepaw licking. MK771 has the potential for the research of morphine abstinence syndrome[1][2].
Related Catalog
In Vivo MK771 (5 mg/kg;腹腔注射) 诱导小鼠眨眼和前爪舔[1]。 MK771 (10 ng-10 µg/小鼠;i.c.v.) 在小鼠体内产生高热反应[2]。 Animal Model: 20-30 g, male MF1 mice[1] Dosage: 5 mg/kg Administration: I.p. Result: Induced blinking and forepaw licking in both acutely isolated and paired mice. Animal Model: 20-30 g, male MF1 mice[1] Dosage: 0.25-60 mg/kg Administration: I.p. Result: Induced blinking was bell-shaped with an ED50 value of 1.72 mg/kg. Animal Model: 25-30 g, Male Swiss-Webster mice[2] Dosage: 10 ng-10 µg/mouse Administration: I.c.v. Result: Produced a hyperthermic response for 4 h followed by a return to normal temperature.
References

[1]. McCreary AC, et al. The thyrotrophin-releasing hormone analogue MK771 induces tic-like behaviours: the effects of dopamine D1 and D2 receptor antagonists. Eur J Pharmacol. 1999 Mar 12;369(1):1-9.  

[2]. Bhargava HN, et al. Comparative effects of thyrotropin releasing hormone, MK-771 and DN-1417 on morphine abstinence syndrome. Psychopharmacology (Berl). 1985;87(2):141-6.  

Density 1.449g/cm3
Boiling Point 1023.2ºC at 760 mmHg
Molecular Formula C16H22N6O4S
Molecular Weight 394.44900
Flash Point 572.6ºC
Exact Mass 394.14200
PSA 183.55000
LogP 0.69630
Index of Refraction 1.632
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.